CRISPR (pronounced “crisper”) and CAR T-cell therapy are genetic technologies that have generated continued excitement during the last several years. Both technologies are experiencing exponential growth. While CAR T-cell therapy holds great promise in the fight against cancer, significant hurdles remain preventing realization of its full potential. Several innovative approaches are under investigation to overcome these hurdles. The present article provides a peek into this area of innovation by focusing on the invention described in a recently published patent application, WO/2018/115887, relating to novel CAR T-cells engineered using CRISPR.
The post CRISPR Modified CAR T-Cells Bolster Immuno Oncology Arsenal appeared first on IPWatchdog.com | Patents & Patent Law.
Patent
- Enablement
- Fee Shifting
- Litigation
- Looming Leahy Bill Would End Fintiv Practice at PTAB
- Patent Filings Roundup: Trio of Actions Accuse IP Investments of Coordinated Campaign with Intellectual Ventures Backend; Judge Albright Cancels One of 141 WSOU-Asserted Patents; New Magnetar Entity Surfaces
- New Tillis-Leahy Bills to Boost Innovation: The Good, the Bad and the Nonsense
- Where Have All of the Ex Parte Appeals Gone?
- A Kinder, Gentler ‘Death Squad’: Ten Years in, Despite Some Reforms, the USPTO is Still Killing U.S. Patents
Recent Posts
- Looming Leahy Bill Would End Fintiv Practice at PTAB
- Patent Filings Roundup: Trio of Actions Accuse IP Investments of Coordinated Campaign with Intellectual Ventures Backend; Judge Albright Cancels One of 141 WSOU-Asserted Patents; New Magnetar Entity Surfaces
- International: WIPO Reports Increasing Prevalence of Alternative Dispute Resolution for Business-to-Business Copyright Disputes
- New Tillis-Leahy Bills to Boost Innovation: The Good, the Bad and the Nonsense
- Where Have All of the Ex Parte Appeals Gone?